Targets › BTN1A1
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Mar 2027.
May function in the secretion of milk-fat droplets. May act as a specific membrane-associated receptor for the association of cytoplasmic droplets with the apical plasma membrane (By similarity). (UniProt, Q13410)
Open in Phaseline: the race on BTN1A1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| STCube | Nelmastobart BTN1A1 agonist | BTN1A1 | Phase 2 | Non Small Cell Lung Cancer; Metastatic Colorectal Cancer (CRC) | Mar 2027 |
Non Small Cell Lung Cancer (1) Metastatic Colorectal Cancer (CRC) (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.